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Simple Summary: Natural Killer cells have shown promise to treat different malignancies. Several
methods have been described to obtain fully activated NK cells for clinical use. Here, we use different
cell culture media and different artificial antigen presenting cells to optimize a GMP compliant
manufacturing method to obtain activated and expanded NK cells suitable for clinical use.
Abstract: Natural killer (NK) cells represent promising tools for cancer immunotherapy. We report
the optimization of an NK cell activation–expansion process and its validation on clinical-scale.
Methods: RPMI-1640, stem cell growth medium (SCGM), NK MACS and TexMACS were used as
culture mediums. Activated and expanded NK cells (NKAE) were obtained by coculturing total
peripheral blood mononuclear cells (PBMC) or CD45RA+ cells with irradiated K562mbIL15-41BBL or
K562mbIL21-41BBL. Fold increase, NK cell purity, activation status, cytotoxicity and transcriptome
profile were analyzed. Clinical-grade NKAE cells were manufactured in CliniMACS Prodigy. Results:
NK MACS and TexMACs achieved the highest NK cell purity and lowest T cell contamination.
Obtaining NKAE cells from CD45RA+ cells was feasible although PBMC yielded higher total cell
numbers and NK cell purity than CD45RA+ cells. The highest fold expansion and NK purity were
achieved by using PBMC and K562mbIL21-41BBL cells. However, no differences in activation and
cytotoxicity were found when using either NK cell source or activating cell line. Transcriptome profile
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showed to be different between basal NK cells and NKAE cells expanded with K562mbIL21-41BBL or
K562mbIL15-41BBL. Clinical-grade manufactured NKAE cells complied with the specifications from
the Spanish Regulatory Agency. Conclusions: GMP-grade NK cells for clinical use can be obtained
by using different starting cells and aAPC.
Keywords: NK cell immunotherapy; NK cell activation and expansion; NKAE cells; clinical-grade
manufacturing; CliniMACS Prodigy
1. Introduction
Development of new donor lymphocyte infusions products with antitumor reactivity
and reduced graft-versus-host disease (GvHD) risk represents a challenging issue in cancer
immunotherapy. Natural killer (NK) cells are lymphocytes from the innate immunity with
the ability to recognize and target tumor cells without prior sensitization, making them
ideal therapeutic agents to treat cancer [1]. In fact, NK cell infusions are well tolerated,
do not cause GvHD or autoimmunity and have been associated with complete remission
in poor-prognosis patients with acute myeloid leukemia (AML) [2,3]. One limitation of
using NK cells as a therapeutic tool is that they have to be fully activated and have to be
infused in large numbers to observe a clinical benefit. However, activation status and NK
cell numbers are low in the main sources of NK cells: PBMCs or umbilical cord blood units.
To overcome this limitation, different protocols have been designed to expand and activate
NK cells ex vivo before transfer to the patient. They may differ in the addition of different
cytokines [4–7], the source of NK cells used [8,9], or the coculture with distinct irradiated
feeder or artificial antigen presenting cells (aAPC) [10–12], among others. Nevertheless, ex
vivo activated and expanded NK cells (NKAE) share some common features [13]. In general,
ex vivo NKAE cells show an increased activation status and increased cytotoxicity, even
responding against tumor targets apparently resistant to NK cell lysis [10,14,15].
Several groups have developed aAPC by engineering the K562 cell line to express
the membrane-bound form of interleukin (IL)-15 (mIL-15) or IL21 and CD137 ligand.
The combination of activating signals provided by the K562 cell line, costimulation via
4-1BBL (CD137L) and survival signals provided by cytokines such as IL15 or IL21 can
mediate NK cell proliferation and the expansion of highly cytotoxic NK cells [11,12].
Besides, the transfer of these protocols to the clinical scale in a manageable, good
manufacturing practice (GMP)-compliant way is still challenging. The multitude of neces-
sary hands-on steps complicates the routine use of these scaled-up manual approaches as
standard therapy. Recently, Miltenyi Biotec has allowed the automated clinical-scale man-
ufacturing of NK cells using centrifugation, magnetic cell separation and cell cultivation
within a closed system, namely the CliniMACS Prodigy [16]. By using this device, different
groups have designed and optimized successful NK cell expansion protocols [17–19].
In parallel, improvements are also in development concerning T-cell depletion of the
allogeneic hematopoietic stem cell transplantation (HSCT) graft, as it may lead to increased
graft failure, relapse and infections due to delayed immune recovery. The selective de-
pletion of the CD45RA+ subset can reduce GvHD through removal of naïve T cells [20].
This fraction, usually discarded, contains NK cells and potentially could be used as a
starting material in the ex vivo activation and expansion of NK cell products.
The objective of this study was to optimize a protocol to activate and expand NK cells
by comparing different cell culture media, different aAPC and using different starting cells.
The most suitable expansion protocols have been further validated within the CliniMACS
Prodigy system to obtain clinical-grade NKAE cells for cancer immunotherapy. In summary,
automated manufacturing clinical grade NK cells in CliniMACS Prodigy is feasible and
NK cell products met the requirements established for the clinical use of this product by
the Spanish Regulatory Agency.
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2. Results
2.1. Optimization of Cell Growth Culture Media
2.1.1. NK Cells Fold Expansion and Purity Using Different Culture Media
In order to compare fold increase and purity of NK cell expansion using different
growth media, we performed a total of 21 expansion experiments with buffy coats from five
different healthy donors. In these experiments, PBMCs were cocultured with previously
irradiated K562-mb15-41BBL (from now on, K562mbIL15) cells in a 1:1.5 ratio in the
following media: RPMI, Stem cell growth medium (SCGM), NK MACS, TexMACS GMP,
all of them supplemented with 5%AB human serum and IL-2.
Fold increase of total cells and NK cells, after 21 days culture with the different media
is shown in Figure 1. Although we did not observe statistically significant differences in
the number of total cells or NK cells expanded; NK MACS yielded the highest NK cells
fold increase (903 ± 576.3) and RPMI medium the lowest (388 ± 292.7) (p = 0.45) (Figure 1).




Figure 1. Fold increase of total cells and natural killer (NK) cells after the 21 days’ culture with the different media. Error 
bars show mean ± SEM. RPMI, SCGM and NK MACS n = 5. TexMACS n = 6. Geometrical symbols represent individual 
data of expanded cells from different donors by using RPMI (dots), SCGM (squares), TexMACS (triangles), NKMACS 
(inverted triangles). 
 
Figure 2. NK cell purity and T cell contamination on activated and expanded NK cells (NKAE) expanded with different 
culture media. Error bars show mean ± SEM. RPMI, SCGM and NK MACS n = 5. TexMACS n = 6. * p < 0.05. Geometrical 
symbols represent individual data of expanded cells from different donors by using RPMI (dots), SCGM (squares), 
TexMACS (triangles), NKMACS (inverted triangles). 
2.1.2. Expression of Activating and Inhibitory Receptors on NKAE Cells 
The phenotype of NKAE cells was evaluated by flow cytometry (FCM) at baseline 
and at day 21 following ex vivo expansion with K562mbIL15 cell line in RPMI, SCGM, NK 
MACS or TexMACS medium. We found that the surface expression of the functionally 
relevant receptors CD25, CD69, NK group-2 member D receptor (NKG2D), NKp30, 
NKp44, NKp46 and DNA accessory molecule 1 (DNAM-1) was upregulated in NKAE 
cells cultured with all media when compared with resting NK cells. However, significant 
differences were only observed in NKG2A and NKp46 receptors when comparisons were 
Figure 1. Fold increase of total cells and natural killer (NK) cells after the 21 days’ culture with the
different media. Error bars show mean ± SEM. RPMI, SCGM and NK MACS n = 5. TexMACS n = 6.
Geometrical symbols represent individual data of expanded cells from different donors by using
RPMI (dots), SCGM (squares), TexMACS (triangles), NKMACS (inverted triangles).
Regarding purity, TexMACS GMP medium yielded the highest NK cell purity at day
21 (92.93% ± 2.8%), followed by NKMACS (91.75% ± 1.82%), with no significant differ-
ences between them. SCGM showed modest NK cell purity (81.79% ± 4.05%). Those cells
cultured with RPMI showed the lowest NK cell purity (72.97% ± 3.6%), and the dif-
ference was statistically significant when compared to TexMACS (p < 0.05). NKMACS
medium and TexMACS showed similar percentages of residual T cells (3.5% ± 0.96%)
and (4.21% ± 2.08%), respectively, and lower than those obtained with SCGM (7.33% ±
2.62%). The highest T cell contamination was observed in those NKAE cells cultured with
RPMI (10.86% ± 1.47%) although the difference with the other media was not significant
(Figure 2).
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Figure 2. NK cell purity and T cell contamination on activated and expanded NK cells (NKAE)
expanded with different culture media. Error bars show mean ± SE . RPMI, SCGM and NK MACS
n = 5. TexMACS n = 6. * p < 0.05. Geometrical symbols represent individual data of expanded
cells from different donors by using RPMI (dots), SCGM (squares), TexMACS (triangles), NKMACS
(inverted triangles).
Additionally, percentages of the different subpopulations, including NK bright and
NK dim, and cell viability at different time p i ts during the culture are indicated in
Table S1. We did not observe differences in viability in the different NKAE cell products
obtained with the different media. The percentage of bright NK cells was statistically
significantly higher when RPMI was used for the expansion, compared to the other three
media. Consequently, the percentage of dim NK cells was lower in those NKAE cells;
however, only statistically significant differences were observed when these NKAE cells
were compared to those obtained using TexMACS. No statistically significant differences
were observed in the percentage of NKT or B cells expanded at day + 21.
2.1.2. Expression of Activating and Inhibitory Receptors on NKAE Cells
The phenotype of NKAE cells was evaluated by flow cytometry (FCM) at baseline
and at day 21 following ex vivo expansion with K562mbIL15 cell line in RPMI, SCGM, NK
MACS or TexMACS medium. We found that the surface expression of the functionally
relevant receptors CD25, CD69, NK group-2 member D receptor (NKG2D), NKp30, NKp44,
NKp46 and DNA accessory molecule 1 (DNAM-1) was upregulated in NKAE cells cultured
with all media when compared with resting NK cells. However, significant differences
were only observed in NKG2A and NKp46 receptors when comparisons were established
between basal NK cells and NKAE cultured with TexMACS (p = 0.01) basal NK cells vs.
NKAE RPMI, respectively (p = 0.013) (Figure 3).
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We next evaluated the cytolytic activity of NKAE cell products obtained using the
different gro th media against K562 target cells and we observed no significant differences
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Figure 4. Cytotoxicity of NKAE cells expanded with different culture media against K562 cells.
The NKAE cells expanded with the different culture media did not show fferences in their cytolytic
ability against K562 cells. Error bars show mean ± SEM. n = 3 for each condition.
2.2. Use of CD45RA+ Cells as a Source of NK Cells to Obtain NKAE
CD45RA+ cells are enriched in naïve T cells and NK cells. This fraction is depleted
and discarded in some HSCT procedures to remove alloreactive T cells and reduce the risk
of GvHD. On the contrary, CD45RA– memory T cells show decreased alloreactivity and
lack naïve T cells, thus improving engraftment and protecting the recipient from infections.
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CD45RA– cells can be infused into patients undergoing haploHSCT either as part of the
graft, along with the mobilized CD34+ cells, or as donor lymphocyte infusions (DLI).
CD45RA+ depleted grafts are usually obtained from healthy donors after pharmacologic
mobilization of hematopoietic stem cells using G-CSF [21], although some other protocols
use non-mobilized apheresis [22]. CD45RA+ depleted fractions for DLI are obtained after
non-mobilized apheresis [23]. To evaluate the feasibility of expanding NK cells using the
CD45RA+-wasted fraction, we performed expansions from CD45RA+ cells obtained after
mobilized and non-mobilized apheresis and compared them with expansions using PBMCs.
According to the NK cell purity data previously obtained, we used TexMACS growth
medium for these expansions. The basal (preculture) composition of the different starting
cell products is shown in Figure 5. CD45RA+ cells from mobilized apheresis showed
the lowest percentage of initial NK cells purity (1.7% ± 0.6%) followed by CD45RA+
cells from non-mobilized apheresis (7.5% ± 2.5%) and PBMCs that had the highest basal
percentage of NK cells (16.9% ± 2.7%). Total cells at the beginning of the expansion are
shown in Figure S1. Fold expansion of NK cells, NKT cells, T cells and B cells after 21
days are shown in Figure 6. CD45RA+ mobilized fraction showed the lowest NK cells fold
expansion (7.6 ± 4.2 fold); (p = 0.011 compared to PBMC) and the highest B cells expansion
this difference was statistically significant when compared to PBMCs (306.3 ± 79.9 fold);
p = 0.014.
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Figure 5. Cell subsets contained in PBMC, CD45RA+ cells from mobilized apheresis (mob) and
CD45RA+ cells from non-mobilized apheresis (non-mob) before NK cell expansion. Mobilized
CD45RA+ cells contain less NK and more B cells compared to PBMC p = 0.03 and p = 0.01 respectively.
PBMC (n = 5), non-mob (n = 3) and mob (n = 3). Error bars show mean ± SEM. * p < 0.05.
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of expanding NK cells from CD45RA+ fraction, we next wanted to explore if there were 
differences in those NKAE cells expanded with K562mbIL15 or K562-mb21-41BBL (from 
now on K562mbIL21) stimulatory cell lines. In these experiments, we expanded NK cells 
from six different donors, using PBMCs or CD45RA+ cells as starting material and 
TexMACS as expansion medium. At 21 days of culture, we evaluated total cell expansion, 
NK cell purity (percentage), cytotoxicity against four different pediatric tumor cell lines: 
A673 (sarcoma), RH30 (rhabdomyosarcoma), Jurkat (T-ALL), LAN-1 (neuroblastoma) and 
K562 cells as control. PBMC tended to yield higher total cell numbers and NK cell purity 
compared to CD45RA+ (2.34 × 108 ± 5.04 × 107 vs. 1.08 × 108 ± 4.38 × 107, p = 0.004) and 
(72.26% ± 25.54% vs. 65.06% ± 22.68%, p = 0.015) respectively. When PBMC were used as 
Figure 6. Fold increase of the different cell subsets in NKAE cells obtained from PBMC, CD45RA+
mobilized apheresis and CD45RA+ non-mobilized apheresis at day + 21. Those NKAE cells expanded
from mobilized apheresis had less NK cells at the end of the expansion compared to NKAE cells
from PBMC and non-mob apheresis. PBMC (n = 5), non-mob (n = 3) and mob (n = 3). Error bars
show mean ± SEM. * p < 0.05.
2.3. Expansion of NKAE Cells by Using Different aAPC
Once we had determined the best suited cell culture media and proven the feasibility
of expanding NK cells from CD45RA+ fraction, we next wanted to explore if there were
differences in those NKAE cells expanded with K562mbIL15 or K562-mb21-41BBL (from
now on K562mbIL21) stimulatory cell lines. In these experiments, we expanded NK
cells from six different donors, using PBMCs or CD45RA+ cells as starting material and
TexMACS as expansion medium. At 21 days of culture, we evaluated total cell expansion,
NK cell purity (percentage), cytotoxicity against four different pediatric tumor cell lines:
A673 (sarcoma), RH30 (rhabdomyosarcoma), Jurkat (T-ALL), LAN-1 (neuroblastoma) and
K562 cells as control. PBMC tended to yield higher total cell numbers and NK cell purity
compared to CD45RA+ (2.34 × 108 ± 5.04 × 107 vs. 1.08 × 108 ± 4.38 × 107, p = 0.004)
and (72.26% ± 25.54% vs. 65.06% ± 22.68%, p = 0.015) respectively. When PBMC were
used as starting cells, expansion with K562mbIL21 yielded hig er total cell numbers than
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using K562mbIL15 (3.36 × 108 ± 6.63 × 107 and 1.3 × 108 ± 5.03 × 107, respectively,
p = 0.03) and tended to achieve higher NK cell purity (84.67 ± 4.82 vs. 59.85 ± 12.42 p
= 0.09). When CD45RA+ cells were used, those expansions using K562mbIL21 tend to
show higher total cells (7.31 × 107 ± 2.18 × 107 vs. 1.32 × 108 ± 8.7 × 107) and NK
cell purity (73.91% ± 5.82% vs. 56.2% ± 11.11%) than those using K562mbIL15, although
these differences were not statistically significant (p = 0.0.53 and p = 0.19 respectively).
NKAE cells obtained after coculture with K562mbIL15 tended to yield lower cell numbers
(1.02 × 108 ± 2.75 × 107 vs. 2.34 × 108 ± 6.07 × 107, p = 0.023) and achieved less NK
cell purity (58.03% ± 7.97% vs. 79.29% ± 3.95%, p = 0.003) than those expanded with
K562mbIL21, no matter the source of NK cells that were used (PBMC or CD45RA+) (Figure
7). Representative data of NK cell purity analyzed by FCM along the expansion procedure
in the different conditions are shown in Figure S2. The flow cytometry analysis showed
a comparable expression of surface markers in all NKAE cell products regardless of the
NK cell source and the aAPC used for the expansion (Figure 8). Representative data of NK
cell receptors expression in PBMC and CD45RA+ cells in basal conditions and in NKAE
cells at day + 21 of expansion are shown in Figure S3. Consequent with the expression of
activating receptors, the different NKAE cells had similar cytolytic ability against the five
different tumor cell lines tested (Figure 9).
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Figure 7. Total cell numbers, NK cell purity and fold expansion of total and NKAE cells using
different NK cell sources and different artificial antigen presenting cells (aAPC) (n = 6 in each
condition). Error ars show mean ± SEM. * p < 0.05, ** p < 0.01. Geometrical symbols represent
individual data of NKAE obtained from different donors in the conditions specified in the X axis. Dots:
PBMC+K562mbIL15; Squares: PBMC+ K562mbIL21, triangles: CD45RA+ K562mbIL15, inverted
triangles: CD45RA+ K562mbIL21.
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Figure 9. Cytotoxicity of NKAE cells expanded from PPBMC or CD45RA+ cells using K562mbIL15
or K562mbIL21 as aAPC. No differences in antitumor ability were observed among the different
NKAE cell products. Error bars show mean ± SEM. E:T ratio was 2:1. Geometrical symbols represent
individual data of NKAE obtained from different donors in the conditions specified in the X axis. Dots:
PBMC+K562mbIL15; Squares: PBMC+ K562mbIL21, triangles: CD45RA+ K562mbIL15, inverted
triangles: CD45RA+ K562mbIL21.
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2.4. Transcriptome Analysis of Basal NK Cells and Different NKAE Cell Products
To further explore the differences in gene expression of basal NK cells obtained from
PBMC or CD45RA+ and their respective NKAE cell products expanded with different
aAPC (K562mbIL15 or K562mbIL21), RNAseq analysis of two representative donors was
performed.
Unsupervised hierarchical clustering of the 15,919 genes remaining after filtering di-
vided the samples into two groups: basal NK cells and NKAE cell products
(Figure 10A). NKAE cells were in turn separated into IL21 and IL15-stimulated cells,
but no cluster of PBMC and CD45RA+-derived NKAE cells was observed. We found a
total of 2185 differentially expressed genes (DEGs) in unstimulated and stimulated NK
cells. Of the 2185 DEGs, 1178 were upregulated and 1007 were downregulated in stim-
ulated NK cells at a false discovery rate (FDR) of 0.05 and log fold change (log FC) of 2
(Figure 10B). A comprehensive list of the top DEG is provided in Table S2. Kyoto Ency-
clopedia of Genes and Genomes (KEGG) pathway analysis showed that the DEGs were
concentrated in 30 pathways, most of them related to cell growth, cell death and metabolism
(cell cycle, hematopoietic cell lineage, p53 signaling pathway, pyrimidine metabolism, etc.)
(Table 1). In addition, the DEG was grouped according to their associated gene ontology
(GO) terms. While overexpressed genes clustered to biological processes such as cell divi-
sion, DNA replication and cell proliferation, under expressed genes were involved in cell
adhesion and cell migration.
Comparison of IL21 and IL15-stimulated NKAE cells led to the identification of
609 DEGs, 29 of them showing upregulation and 580 showing downregulation in IL21-
stimulated NKAE cells (Figure 10C and Table S3). The number of DEGs between IL21 and
IL15-stimulated NKAE cells was larger when the cell source was PBMC compared with
CD45RA (547 vs. 381 DEGs). The 22 enriched pathways were related to the inflammatory
response and the immune system (cytokine–cytokine receptor interaction, hematopoietic
cell lineage, asthma, inflammatory bowel disease (IBD), primary immunodeficiency, IL-17
signaling pathway, etc.) (Table 1). GO term enrichment analysis showed cluster to biological
processes such as immune response, inflammatory response, phagocytosis, complement
activation, B cell receptor signaling pathway and cell adhesion.
Many cytokines and cytokine receptors involved in cell differentiation and activation
were overexpressed under IL15 stimulation when compared with IL21 stimulation (CD5,
CD4, CD8B, CD3G, CD19, CD22, CD24, CD20, CD23, CD35, IL4, IL5, CD116, CD123,
CD33, CD126, CD13, IL1A, IL1B, CD121, IL9R, CD125, CD36 and CD41). Regarding
the expression of NK activating and inhibitory receptors, we only identified one killer-
cell immunoglobulin-like receptor (KIR) gene differentially expressed between IL21 and
IL15-expanded NK cells, KIR2DL3, which was overexpressed in IL-21-expanded NK
cells. Differences in the expression of leukocyte immunoglobulin like receptor B1 (LIR1),
natural-killer group 2 member A (NKG2A), C (NKG2C) and D (NKG2D) and natural
cytotoxicity receptors (NCRs) were not found. Concerning inhibitory checkpoint receptors,
programmed cell death 1 (PD1) was overexpressed in IL15-expanded NK cells. We did not
find significant changes in the expression of markers of apoptosis and proliferation such as
caspase 3 (CASP3), caspase 8 (CASP8), BCL2 apoptosis regulator (BCL2), BCL2 associated X
apoptosis regulator (BAX), BCL2-Like 14 apoptosis facilitator (BCL2L14), cyclin dependent
kinase inhibitor 2A (CDKN2A), telomerase reverse transcriptase (TERT), MYB proto-
oncogene like 2 (MYBL2), BUB1 mitotic checkpoint serine/threonine kinase (BUB1), polo
like kinase 1 (PLK1), cyclin E1 (CCNE1), cyclin D1 (CCND1) and cyclin B1 (CCNB1).
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Figure 10. Gene expression profiles of basal NK cells and NKAE cell products. (A) Unsupervised
hierarchical clustering of NK cells using the 15,919 genes remaining after filtering. (B) Heat map
of normalized expr ssion value for 2185 genes that are differentially expressed between basal
NK cells and NKAE cell products. (C) Heat map of normalized expression values for 609 genes
that are differentially expressed between IL21 and IL15-stimulated NKAE cells. (D) Heat map of
normalized expression values for 48 genes that are differentially expressed between PBMC and
CD45RA+-derived NKAE cells. H at map colors correspond to gene expression as indicated in the
color key: red (overexpressed) and blue (underexpressed). Each row in the heatmap represents a gene
and each column, an individual sample. Deep red line: basal NK cells, green line: IL15-stimulated
PBMC-derived NKAEs, yellow line: IL15-stimulated CD45RA-derived NKAEs, light blue line: IL21-
stimulated CD45RA-derived NKAEs, emerald green line: IL21-stimulated PBMC-derived NKAEs.
Finally, a small number of DEGs was observed between PBMC and CD45RA+-derived
NKAE cells. Of the 48 DEGs, 37 showed upregulation and 11 downregulation in PBMC-
derived NKAE cells (Figure 10D and Table S4). No KEGG pathways or GO terms were
significantly enriched for the DEG genes. Nevertheless, among the IL21-stimulated NKAE
cells, two pathways were enriched when comparing PBMC and CD45RA-derived NKAE
cells: hematopoietic cell lineage and arachidonic acid metabolism.
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Table 1. KEGG pathways enrichment analysis by differentially expressed genes (DEGs).
Nº of Differentially Expressed
Genes KEGG Significant Pathways
NKAE vs. basal NK cells 2185 DEG(1178 UP + 1107 DOWN)
Cell cycle, Cytokine-cytokine
receptor interaction, Viral protein
interaction with cytokine and
cytokine receptor, Hematopoietic
cell lineage, p53 signaling





Biosynthesis of amino acids,




Small cell lung cancer, MAPK
signaling pathway, Oocyte
meiosis, Human T-cell leukemia
virus 1 infection, Chemokine
signaling pathway, Leishmaniasis,
Cellular senescence, Starch and
sucrose metabolism, Tryptophan





IL21 vs. IL15-stimulated NKAE
cells
609 DEG




bowel disease (IBD), Primary
immunodeficiency, IL-17
signaling pathway, Viral protein
interaction with cytokine and
cytokine receptor, Leishmaniasis,




Protein digestion and absorption,
Chemokine signaling pathway, T




Malaria, NF-kappa B signaling
pathway, Cell adhesion molecules
(CAMs), Ether lipid metabolism
PBMC vs. CD45RA+ derived
NKAE cells
48 DEG
(37 UP + 11 DOWN) -
2.5. Production of Clinical Grade NKAE Cells in CliniMACS Prodigy
After the optimization of the conditions to better expand NK cells, we wanted to test
the feasibility of manufacturing these NKAE cells for clinical use. To this aim, we performed
a clinical-scale completely automated expansion procedure using the CliniMACS Prodigy®
device (Miltenyi Biotec, Bergisch Gladbach, Germany). According to our previous results,
we used non-mobilized apheresis as a starting material and TexMACS GMP-compliant
medium (Miltenyi Biotec, Bergisch Gladbach, Germany). For the clinical manufacturing,
GMP-compliant additional steps of CD3 depletion and CD56 selection were performed to
abbreviate NK cell expansion times. Either irradiated K562mbIL15 or K562mbIL21 cells
were used as aAPC.
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A total of 2–2.5 × 106 of purified CD56+ cells were cocultured with 40 × 106 of
irradiated K562mbIL15 or K562mbIL21 cells, at an approximate ratio of 1:20. Viability,
number of total cells, percentage and number of NK cells of starting CD56+ cells at days
+7 and +14 of coculture are shown in Table 2. FCM data showing NK cell purity along the
manufacturing process are shown in Figure S4.
Table 2. Characteristics of CD56 starting cells and expanded NKAE cells a day +7 and +14 (end of
culture). (*) Viability measured in CD45+ cells. (**) At day 0, analysis was performed in CD56+ cells
before coculture with K562mbIL15 cells.
K562mbIL15 % Viability(*) % NK Cells % T Cells Total Cells
Total NK
Cells
Day 0 (**) 96 87 22.8 2.9 × 106 2.5 × 106
Day +7 95 87.1 1 80 × 106 76 × 106
Day +14 97 97.1 1.2 654 × 106 635 × 106
K562mbIL21 % Viability(*) % NK Cells % T Cells Total Cells
Total NK
Cells
Day 0 (**) 96 77 14.8 3.4 × 106 2 × 106
Day +7 99.3 90.7 3.5 107.5 × 106 97.5 × 106
Day +14 97 93 1.6 1498 × 106 1393 × 106
On day 0, before the expansion, both CD56+ cells and aAPC met the acceptance criteria
(sterility, mycoplasma negative and viability ≥70%).
At the end of coculture (Day +14), NKAE cells expanded in CliniMACS Prodigy
showed an upregulation of all the receptors analyzed (Figure 11).
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The acceptance criteria for the manufactured NKAE cells at the end of the process
included: viability ≥70%, cytotoxicity against K562 cells at an 8:1 E:T ratio ≥50%, my-
coplasma negative, sterility (0 colony forming units, CFU), endotoxins ≤0.25 EU/mL,
undetectable bcr/abl (absence of residual aAPC) and no overexpression of oncogenic genes
C-MYC and TERT. As shown in Table 3, the manufactured NKAE cell products complied
with the specifications and met the release criteria and, thus, were suitable for clinical use.
Table 3. The manufactured NKAE cells met the established acceptance criteria.
aAPC Sterility Mycoplas a Endotoxins c-myc/ ert Bcr/abl Cytotoxicity
K562mbIL15 0 CFU Negative <0.01EU/mL
No
expression 0% 79%
K562 I 21 0 Ne ati e <0.03EU/mL
No
expression 0 100%
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3. Discussion
Natural killer cells can rapidly kill tumor cells, and have been used in clinical trials
to treat patients with different malignancies [24]. In this context, significant progress has
been made in NK-cell based therapies, both in haploidentical stem cell transplantation
(haploSCT) [25–27] or the non-transplant setting [28–30], since NK cells contribute to the
graft versus leukemia/tumor (GvL/GvT) effect with no signs of GvHD [26,27,31].
The clinical use of NK cells as therapeutic weapons against cancer has some limitations:
(1) these cells represent a small fraction of peripheral white blood cells and large numbers
are needed to achieve clinical benefits and (2) NK cells need to be fully activated to
induce tumor cell killing. Overcoming these limitations rely on the development of GMP-
compliant manufacturing methods. Several protocols to obtain fully activated NK cells
for clinical use have been developed. They may differ (among others) in the source of NK
cells used: PBMC [32], umbilical cord blood [33] and NK-92 cell line [34]; the addition of
different activating cytokines [7,35] or in the use or not of stimulating feeder cells [14,34–36].
The aims of this study were (1) to optimize in small scale NK cell activation and
expansion protocol, (2) to test the feasibility of large-scaling this procedure to manufacture
NKAE cells emulating a clinical application and (3) to demonstrate that the manufactured
NKAE cell products met the requirements established by the Spanish Regulatory Agency
for clinical use. To optimize the best cell culture growth media, we expanded NK cells
by coculturing PBMC with irradiated K562mbIL15 in four different GMP-grade growth
media (RPMI, SCGM, TexMACs and NK MACS). We found all the cell culture media
used yielded similar numbers of total cells and NK cells. Although RPMI expanded lower
numbers of cells, the differences with the rest of the media were not statistically significant.
TexMACS and NK MACS showed the highest percentage of NK cells and the lowest T cell
contamination, indicating they should be the preferred growth culture media to obtain the
purest NKAE cell products. These results are similar to those published by Klöß et al. [19],
showing NK MACs as the best culture medium when compared with X-VIVO-10, SCGM
and TexMACS. However, in this publication, compared to the NK cell proliferation in the
NK MACS medium, cell expansion rates in the other cell cultures containing X-VIVO-10,
SCGM or TexMACS media were significantly lower. These differences could be explained
by the continued use of higher concentrations of IL-2 in their experiments (1000 IU/mL vs.
10–100 IU/mL), or the use of different starting cells (purified CD56+CD3+ cells instead of
total PBMC), and the coculture of starting cells with irradiated aAPC in our experiments.
The lowest total cell and NK cells fold expansion that we observed in those cultures
containing RPMI are in line with the observations of Duck et al. who described a better
activation and expansion of NK cells when using SCGM compared to RPMI-1640 [37].
Once we had optimized the cell culture medium, we tested the feasibility of obtaining
NKAE cells from CD45RA+ fraction. CD45RA− cells were enriched in the central memory
and effector memory T cells and had the ability to target previous pathogens or vaccines.
Additionally, CD45RA– cells decreased alloreactivity and lacked naïve T cells, responsible
for GVH reactions. One way to protect the host from infections after HSCT is to infuse
CD45RA– cells as DLI [38]. CD45RA– cells are obtained upon depletion of CD45RA+ cells.
This fraction is enriched in naïve T cells and NK cells, and thus, could be a potential source
of NK cells to obtain NKAE cells. When CD45RA+ cells from G-CSF mobilized apheresis
were used to obtain NKAE cells, no expansion of either total or NK cells was observed.
However, those CD45RA+ cells from non-mobilized apheresis yielded similar numbers
of total and NK cells to those obtained from total PBMC, proving the feasibility of using
this cell fraction as a source of NK cells to obtain NKAE. The inability to expand NK cells
from G-CSF mobilized apheresis that we observed could be somehow expected, as the
negative impact of G-CSF on NK cells mobilization and cytotoxicity has been previously
reported [39,40]. In the future, if mobilization of progenitor hematopoietic cells is needed,
we could consider the use of plerixafor, as it has been proved to effectively mobilize NK
cells to the peripheral blood [41].
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After we proved the feasibility of expanding NK cells from CD45RA+ fraction, we
analyzed potential differences in NKAE cells obtained from total PBMC or CD45RA+ cells
after coculture with irradiated K562mbIL15 or K562mbIL21 cells. Taking into account
only the source of NK cells used, we observed a higher fold increase of total and NK cells
when PBMC were used compared to CD45RA+ cells. Additionally, when K562mbIL21 cells
were used as aAPC larger numbers of total cells and higher NK cell purity were achieved,
regardless of the NK cell source used. All these data taken together suggest that coculture
of PBMC with K562mbIL21 cells should be the method of choice to achieve large numbers
of purified NKAE cells. The enhanced proliferation ability of K562mbIL21 expanded NK
cells was demonstrated before [42]. In this report, Denman C J et al. observed that those
NK cells that expanded with K562mbIL21 presented less senescence and longer telomeres
than those expanded with K562mbIL15, suggesting this could be a possible mechanism
to explain their sustained proliferation. Nevertheless, the NKAE cells obtained by using
different NK cell sources or aAPC, showed a similar expression of NK cell receptors and
comparable antitumor cytotoxicity in vitro against different tumor cell lines.
When transcriptome was analyzed, marked differences were observed in the gene
expression profile of stimulated and unstimulated NK cells, with DEGs mostly related
to cell growth and metabolism. These changes in gene expression reflect the activation
and expansion taking place during NK stimulation. Some of these DEGs have been
previously identified with high fold change when comparing expanded and unstimulated
NK cells [11,43] such as ubiquitin conjugating enzyme E2 C (UBE2C), thymidine kinase
1 (TK1), aurora kinase B (AURKB), ribonucleotide reductase regulatory subunit M2 (RRM2)
and ficolin 1 (FCN1), and many of them are involved in cell cycle progression.
A high number of DEG was identified between IL21 and IL15-stimulated NKAE cells,
especially when the cell source was PBMC. These results indicate that IL21 and IL15 had
different effects on NK cell expansion, producing changes in the expression of different
cytokines and cytokine receptors. Most of the DEG were downregulated in IL21-stimulated
NKAE cells when compared with IL15-stimulated NKAE cells. Since these genes were
involved in pathways such as hematopoietic cell lineage, chemokine signaling pathway,
JAK-STAT signaling pathway and PI3K-Akt signaling pathway, the differential expression
of these genes could promote a more undifferentiated phenotype of NK cells under IL21
stimulation, while a more activating phenotype could be associated to IL15 stimulation.
When comparing IL21 and IL15-expanded NK cells, Denman et al. [42] found similar
expression profiles, with CD160 as the only differentially expressed gene. Nevertheless,
only 96 genes were assessed by these authors in contrast to the 15,919 genes analyzed in this
work, which explains the lack of overlap between both studies. In addition, these authors
observed an increase in the proliferation of IL21-expanded NK cells, which was associated
with an increased in telomere length. In the present study, although we observed a
more proliferative phenotype of IL21-expanded NK cells, we did not find an increase in
the expression of telomerase reverse transcriptase (TERT) and other genes involved in
telomere length regulation. However, the decrease in cytokines and cytokine receptors
related to cell differentiation could explain a more proliferative phenotype. The similar
expression of cytotoxicity receptors observed in the transcriptome analysis between IL21
and IL15-expanded NK cells is in accordance with the comparable surface expression of
NK cell receptors observed in FCM, and the functional experiments, where no significant
differences in cytotoxicity were observed.
In sum, we observed a similar gene expression profile between PBMC and CD45RA+-
derived NKAE cells, which suggests that stimulation of both cell sources give rise to NKAEs
with similar phenotypes, and this hypothesis was confirmed at least in part through the
analysis of the surface expression of NK cell receptors by FCM. Nevertheless, when IL21-
stimulated, PBMC-derived NKAE cells showed downregulation of the hematopoietic
cell lineage pathway, suggesting a more proliferative phenotype than CD45RA+-derived
NKAE cells. These results were in accordance with the cell culture experiments, where
PBMC-derived NKAE cells expanded more than CD45RA+-derived NKAE cells.
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Once we had optimized the cell culture growth medium and the preferred NK cells
source, we moved a step further to translate these protocols to the clinical and we manufac-
tured clinical-grade NKAE cells in GMP-compliant conditions. We ran two manufacturing
processes in CliniMACS Prodigy coculturing CD56+ cells with irradiated K562mbIL15 or
its counterpart aAPC with IL21. In the clinical setting is critical to consider two important
issues (1) the need to infuse the patients as early as possible and (2) to avoid undesirable
GvH reactions caused by residual T cells. Thus, in an attempt to shorten the NK cell
expansion times and minimize the risk of T cell contamination in the final NKAE cell
products, we used already purified CD56+ cells instead of total PBMC as starting cells.
Both protocols using either K562mbIL15 or K562mbIL21 achieved large numbers of fully
activated and highly cytotoxic NKAE cells, and these manufactured NK cell products
met the release criteria and complied with the specifications from the Spanish Regulatory
Agency for manufacturing under aseptic conditions. However, co-culture of CD56+ cells
with K562mbIL21 cells yielded an NK cell fold increase 2.7 times higher, and the NKAE
cells showed a more potent cytolytic capacity against K562 cells than those expanded with
K562mbIL15 cells. Indicating that, as we had observed in the small-scale research-grade
experiments, the use of K562mbIL21 cells as aAPC could be advantageous. Nevertheless,
it is important to note that only one GMP-grade large-scale manufacturing process with
each cell line and using two different healthy donors was performed, for this reason, the
differences that we observed could also be explained, at least in part, by the interdonor
variability. In previous clinical trials carried out in our group, clinical-grade NKAE cells
were obtained by manual coculture of PBMC and irradiated K562mbIL15 in IL-2+AB
serum-supplemented RPMI [32]. By these means, the total cells, total NK cells and the NK
cell purity (639.78 × 106 ± 435.81, 515.23 × 106 ± 345.03 and 79.93% ± 17.43%, respectively)
were lower than those we obtained in the present study. Thus, the results reported in this
manuscript could demonstrate that the use of CD56+ cells as the starting cells, K562mbIL21
as aAPC, TexMACS as the cell culture growth medium and the CliniMACS Prodigy device
constitute a much more advantageous strategy to obtain clinical-grade NKAE cells.
In summary, we optimized a protocol to expand large numbers of fully functional NK
cells from different sources, culture media and aAPC, and we demonstrated the feasibility
of clinical-scale this procedure by using the CliniMACs Prodigy device, a semiautomated
closed system. The NKAE cells manufactured by these means are suitable for direct
infusion to the patient or cryopreservation and could also serve as a platform for more
advanced NK cell therapies such as a combination with BiKes or genetic modification to
express chimeric antigen receptors (CARs).
4. Materials and Methods
4.1. Source of NK Cells and aAPC
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from
healthy volunteers by using Ficoll–Paque gradient centrifugation. CD45RA+ fractions
were obtained after magnetic enrichment using CD45RA microbeads and running “Possel”
program in the AutoMACS device (both from Miltenyi Biotec) following manufacturer
instructions. As the CD45RA+ fraction is a commonly discarded material from haploiden-
tical transplantation procedures, in some cases, CD45RA+ cells were obtained from the
Hematology Service at Hospital La Paz after written informed consent, in accordance with
the Declaration of Helsinki and La Paz University Hospital Ethics Committee (ethical code
4917), and this study is part of an approved clinical trial with EudraCT: 2016-003578-42.
Buffy coats were obtained from the Transfusions Centre of the Comunidad de Madrid upon
institutional review board approval. All donors complied with the requirements regarding
quality and safety for the donation, obtaining, storage, distribution and preservation of
human cells and tissues under the Spanish specific regulation.
K562mbIL15 and K562mbIL21 cells were kindly provided by Prof. Campana (Na-
tional University Hospital, Singapore) and Prof. Lee (Nationwide Children’s Hospital,
Ohio, EEUU), respectively and irradiated with 100 Gy before coculture.
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4.2. Expansion Procedure
For the culture medium optimization, PBMCs were cocultured with irradiated K562mbIL15
cells in a 1:1.5 ratio in the indicated growth medium: RPMI-1640 (RPMI, Lonza, Basel, Belgium),
stem cell growth medium (SCGM, Cellgenix, Freiburg, Germany), NK MACS (Miltenyi Biotec,
Bergisch Gladbach, Germany) or TexMACS GMP medium (TexMACS, Miltenyi Biotec, Bergisch
Gladbach, Germany). All media were supplemented with 10% human AB serum (Sigma, St.
Louis, MO, USA) and IL-2 (Miltenyi Biotec, Bergisch Gladbach, Germany) at 10 IU/mL for
the first week and 100 IU/mL thereafter. Fresh medium was added every 2 days to a final
concentration of 1–2 × 106 cell/mL.
To explore the feasibility of expanding NK cells from the CD45RA+ fraction, PBMCs or
CD45RA+ cells from mobilized or non-mobilized apheresis were cocultured with irradiated
K562mbIL15 in a 1:1.5 ratio, using complete TexMACs.
To determine the best NK cell source and aAPC, either PBMC or CD45RA+ cells were
cocultured with irradiated K562mbIL15 or K562mbIL21 in a 1:1.5 ratio, using complete
TexMACs.
Total cell expansion, percentage of NK cells and other lymphocyte subpopulations
and viability of the cultures were monitored every week by flow cytometry. Cytotoxicity
of expanded NK cells was tested against different tumor target cells between days 14 and
21 of NK cell expansion.
4.3. Antibodies and Flow Cytometry
Lymphocyte subpopulations were determined in a Navios flow cytometer (Beckman
Coulter, Brea, CA, USA) using the conjugated antibodies listed in Table S5. T lympho-
cytes were defined as CD45+CD3+CD56−, B lymphocytes as CD45+CD19/CD20+, NKT
as CD45+CD3+CD56+ and NK cells as CD45+CD56+CD3− and further subdivided in dim
(CD56dimCD16+) and bright (CD56brightCD16-) subsets.
Expression of functionally relevant receptors was evaluated within the NK population.
FlowJo v10.0.7 software (BD, San Jose, CA, USA) was used for data analysis.
4.4. In Vitro Cytotoxicity Assays
Cytotoxicity of NKAE cells was assayed between days 13 and 20 of expansion by
performing conventional 4 h Europium-TDA assays. K562, Jurkat, A673, RH30 and LAN-
1 cell lines were used as targets. K562, Jurkat, A673 and LAN-1 cells were purchased
from American Type Culture Collection (ATCC). RH30 was kindly provided by Dr. Roma
(Vall D’Hebron Institute of Research, VHIR). All cell lines were cultured following ATCC’s
recommendations and routinely tested for mycoplasma. Conventional 4-h europium-TDA
release assays (Perkin Elmer, Waltham, MA, USA) at different effector:target ratios (starting
at 8:1) were performed as previously described [44].
The following formulas were used to calculate spontaneous and specific cytotox-
icity: % specific release = (experimental release − spontaneous release)/(maximum
release − spontaneous release) × 100%, spontaneous release = (spontaneous release-
background)/(maximum release-background)× 100.
4.5. Gene Expression Profiling
4.5.1. Library Preparation and Sequencing
NK cells from two representative donors (1 and 2) were obtained pre and post-
expansion. Total RNA was isolated using the RNeasy Mini kit (QIAGEN, Hilden, Ger-
many) according to the manufacturer’s instructions. To remove residual genomic DNA,
the RNA samples were digested with DNAse I. The RNA concentration was assessed
by fluorescence quantitation using Qubit 2.0 and the HS RNA assay kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA), the RNA purity by spectrophotometry using Nanodrop
2000 (Thermo Fisher Scientific Inc., Waltham, MA, USA) and the RNA integrity by elec-
trophoresis using TapeStation 4200 RNA ScreenTape (Agilent Technologies, Santa Clara,
CA, USA). Library preparation and RNA sequencing were performed at Nimgenetics Com-
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pany (Madrid, Spain). Library samples were prepared with the TruSeq Stranded mRNA
Library Prep kit (Illumina, San Diego, CA, USA) as recommended by the manufacturer.
Paired-end sequencing (2 × 100 pb) was performed with NovaSeq 6000 system (Illumina,
San Diego, CA, USA), with a minimum of 25 million reads per sample and read quality of
90% > Q30.
4.5.2. RNA Sequencing Analysis of NK Cells
The resulting reads were aligned using HISAT2 and hg19 as a reference. Transcript
assembly and quantification were achieved with StringTie and the differential gene expres-
sion analysis between the different conditions was performed with edgeR [45] using log
fold change (log FC) ≥ 2 and false discovery rate (FDR) < 0.05 as the threshold. Clustered
heatmaps were done with genes that have at least one count per million reads in more
than one sample. The functional analysis was performed with clusterProfiler [46] using the
enrichKEGG function.
4.6. Manufacturing of Clinical-Grade NKAE Cells
In an attempt to shorten the times to obtain clinical-grade NKAE cell products with
highest NK cell purity and less T cell contamination, ready to infuse into the patients with
no further processing, we purified the CD56+ fraction before the expansion. The ex vivo
immunomagnetic purification procedure comprised CD3 depletion followed by CD56
cell selection as previously described [47]. Automated activation and expansion process
were performed in CliniMACS Prodigy instrument using the CliniMACS T520 tubing set
and T cell transduction (TCT) protocol. In detail, at day 0, the coculture was initiated by
using 2 × 106–2.5 × 106 NK cells and 4 × 107 K562mbIL15 or K562mbIL21 cells previously
irradiated with 100 Gy. Cells were cultured in 70 mL of GMP-grade TexMACs medium
supplemented with 5% human AB serum (Sigma) and 100 IU/mL of IL-2 (Miltenyi Biotec).
NK cells were incubated in the culture chamber (37 ◦C and 5% CO2) in a static culture for
the first week. At day +7, agitation was started and 70 mL of fresh complete medium were
added to the culture. Cells were expanded for 14 days before being harvested. Sampling
was performed at day +7 for process controls, including cell counts, viability, analysis of
CD56+/CD3− cell content by FCM, mycoplasma and sterility. At the end of the expansion,
cells were automatically collected in 0.9% sodium chloride solution supplemented with
0.5% human serum albumin (Albutein 20%, Grifols, Barcelona, Spain), in a sterile bag.
Release quality controls: total cell counts, viability, analysis of CD56+/CD3-, CD3+/CD56-
and CD56+/CD3+ cell content by FCM, cytotoxicity against K562 cells, Gram staining,
endotoxins, cell impurities (K562mbIL15 or K562 mbIL21) by qPCR, mycoplasma and
sterility were performed at the end of the process.
4.6.1. Analysis of Cell Count, Viability and NK Cell Purity
NKAE cells were counted in a CELL-DYN Emerald hematology analyzer (Abbott) and
analyzed for their viability, immunophenotype and activation status by FCM as previously
described.
4.6.2. Cytotoxicity
Potency of manufactured NKAE cells was tested by performing Europium-TDA
conventional assays against K562 cells at 8:1, 4:1, 2:1 and 1:1 E:T ratios.
4.6.3. Microbiological Tests
The expansion cell products were tested for sterility, according to Eu Ph 2.6.21. The mi-
crobiological tests were developed by the Clinical Microbiology and Parasitology Service
of HULP by conventional microbiology techniques. In summary, sample tests were inocu-
lated into separate culture media and the growth of viable microorganisms was tested after
several days.
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4.6.4. Analyses of Non-Cellular Impurities
The detection of non-cellular impurities was carried out in accordance with the
methodology recommendations of Chapter 2.6.21 and 2.6.7 of the European Pharmacopeia
(EuPh) for mycoplasma and Chapter 2.6.14 for endotoxins. A DNA-binding dye-based
qPCR system was employed for the detection of mycoplasma DNA in cell cultures. In the
final products, the levels of endotoxins were quantified by the endotoxin test Endosafe-PTS
(Charles River). Both assays were developed by the Clinical Microbiology and Parasitology
Service of HULP.
4.6.5. Analysis of Cellular Impurities
Given that the aAPC used for NK cell activation and expansion is a tumor cell line is
necessary to ensure the absence of residual K562mbIL15 or K562mbIL21 cells in the final
NKAE cells products. Both aAPC contain the fusion gene BCR/ABL, so the presence of
residual cells was analyzed by performing a real-time PCR (RT-PCR) for the Mbcr transcript
as previously described [48].
4.6.6. Genetic Tests
Genetic tests were carried out at the end of the manufacturing process.
The expression of oncogenes c-Myc and telomerase reverse transcriptase (TERT) by
RT-PCR. Briefly, the total RNA was isolated using the RNeasy kit (Sigma), and reverse
transcription was performed with SuperScript IV (Invitrogen, Thermofisher Scientific Inc.,
Waltham, MA, USA). The qRT-PCR was performed on the ABI Prism 7900HT sequence
detection system (Applied Biosystems, Thermofisher Scientific Inc., Waltham, MA, USA),
using the TaqMan universal PCR master mix and TaqMan gene expression assay probes
(Applied Biosystems), according to the manufacturer’s specifications. The assay identifica-
tion numbers were as follows: c-Myc, Hs00153408_m1; TERT, Hs00972656_m1 and GUSβ,
Hs00939627_m1. The thermal cycler conditions were: 10 min at 95 ◦C and 40 cycles of
95 ◦C for 15 s followed by 60 ◦C for 1 min. All the reactions were performed in triplicate.
The amplification data were analyzed with ABI Prism sequence detection software 2.1
(Applied Biosystems) and the relative c-MYC and TERT expression was calculated by
normalization against human GUSβ expression.
To rule out chromosomal aberrations, comparative genomic hybridization (CGH)
was performed in NKAE cells. DNA from the NKAE cell products was isolated using
the AllPrep DNA/RNA Micro Kit (Qiagen, Hilden, Germany) and hybridized with male
reference DNA (Promega Biotech, Alcobendas, Madrid, Spain) on a 60,000 oligonucleotide
CGH-SNP platform (Agilent, Santa Clara, CA, USA). The data were analyzed with Agilent
CGH analytics 3.4 software (Santa Clara, CA, USA), using the statistical algorithm ADAM-2
according to a sensitivity threshold of 6.0 and an average window of 0.5 Mb. Alterations in
the DNA copy number were considered when at least 5 consecutive probes were altered.
Probes were annotated against the human assembly GRCh37 (also known as hg19).
4.7. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software. Results are shown
as mean ± standard error of the mean (SEM). Data sets were analyzed for Gaussian
distribution by using Kolmogorov–Smirnov, D-Agostino and Pearson and Shapiro–Wilk
tests. Those data without normal distribution were compared with non-parametric tests.
Two-tailed Student’s paired t test was used when cells from the same donor in different
conditions were compared. For comparisons between three or more groups, a one-way
ANOVA test was used to determine statistical significance. Dunn’s multiple comparisons
post hoc tests were run in conjunction with one-way ANOVAs and all groups were com-
pared with one another. When two or more variables were compared, two-way ANOVA
tests followed by Bonferroni pot hoc tests to compare replicates were run. In all cases,
a p value of <0.05 was deemed to be statistically significant.
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5. Conclusions
In this report, we optimized a protocol to obtain NKAE cells by using four different
culture growth media (RPMI, SCGM, TexMACs and NKMACs), two different NK cell
sources: PBMC or CD45RA+ cells and two distinct irradiated aAPC (K562mbIL15 or
K562mbIL21). We determined that TexMACs was the most suitable cell culture medium
to expand NK cells. NK cells could be activated and expanded from those CD45RA+
cells obtained from non-mobilized apheresis, although the use of PBMC as the NK cell
source yielded the highest numbers of purified NKAE cells. When K562mbIL21 was
chosen as aAPC, the highest numbers of NKAE cells with less contamination of T cells
were achieved regardless of the NK cell source used. All NKAE cells obtained from either
PBMC or CD45RA+ expanded with K562mbIL15 or K562mbIL21 showed comparable
antitumor ability against sarcoma, T-ALL, CML, neuroblastoma and rhabdomyosarcoma
cells. Finally, we fulfilled clinical manufacturing of NKAE cells in an automated closed
system CliniMACS Prodigy by using CD56+ cells and either irradiated K562mbIL15 or
K562mbIL21. In both processes, sufficient numbers of NKAE cells with high purity and low
T cell contamination were manufactured after 14 days of culture. The different release tests
performed showed that manufactured NKAE cells met the requirements and specifications
from the regulatory agency, and thus were suitable for clinical use.
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